Genes with a spike expression are clustered in chromosome (sub) bands and spike (sub) bands have a powerful prognostic value in patients with multiple Myeloma

Haematologica

Volumn 97, Issue 4, 2012, Pages 622-630

  Kassambara, Alboukadel ^a   Hose, Dirk ^b   Moreaux, Jérôme ^a,c   Walker, Brian A ^d   Rotopopov, Alexei ^f   Reme, Thierry ^a,c   Pellestor, Franck ^a,c,e   Pantesco, Véronique ^a   Jauch, Anna ^b   Morgan, Gareth ^d   Goldschmidt, Hartmut ^b   Klein, Bernard ^a,c,e  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIV MONTPELLIER   (France)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Molecular biology; Myeloma; Prognosis; Spike (sub) bands; Survival

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MAF; TRANSCRIPTION FACTOR MMSET; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME BAND; COPY NUMBER VARIATION; EXPRESSED SEQUENCE TAG; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE TRANSLOCATION; HUMAN; HUMAN CELL; KARYOTYPING; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PROGNOSIS; SPIKE GENE;

CLUSTER ANALYSIS; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 84859476869     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.046821     Document Type: Article

References (46)

1. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23 (12):2210-2221.
2. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010;116(15): e56-e65.
3. Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117(6):2009-2021.
4. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression fol lowing tandem stem-cell transplantation. Blood. 2006;108(5):1724-1732.
5. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. Blood. 1996;88(7):2699-2706.
6. Chng WJ, Gonzalez-Paz N, Price-Troska T, Jacobus S, Rajkumar SV, Oken MM, et al. Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia. 2008;22(12):2280-2284.
7. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NFkappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-144.
8. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-130.
9. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, et al. High-resolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9(4):313-325.
10. Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009;27(27):4585-4590.
11. Crawley JJ, Furge KA. Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol. 2002;3(12): RESEARCH0075.
12. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 2010;10(1):59-64.
13. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177-1183.
14. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116(14):2543-2553.
15. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028.
16. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23 (26):6333-6338.
17. Shaughnessy JD, Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284.
18. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Franco - phone du Myelome. J Clin Oncol. 2008;26 (29):4798-4805.
19. Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009;113(18):4331-4340.
20. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 2009;28(44):3866-3879.
21. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD, Jr., Barlogie B, et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009;113(19):4614-4626.
22. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dys - regulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple Myeloma cell lines [see comments]. Blood. 1996;88:674-681.
23. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92(9):3025-3034.
24. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64(4):1546- 1558.
25. Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I, et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol. 2003;82(10):654-656.
26. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96(4):574-582.
27. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107(7):2633- 2638.
28. Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112(10): 4235-4246.
29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504.
30. Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010;95(7):1150-1157.
31. Popp S, Jauch A, Schindler D, Speicher MR, Lengauer C, Donis-Keller H, et al. A strategy for the characterization of minute chromosome rearrangements using multiple color fluorescence in situ hybridization with chromosome-specific DNA libraries and YAC clones. Hum Genet. 1993;92 (6):527-532.
32. Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer. 2005;44(2):194-203.
33. Hose D, Rossi JF, Ittrich C, DeVos J, Benner A, Reme T, et al. A New molecular classification of multiple myeloma using gene expression profiling and fluorescence in situ hybridisation as predictor for event free survival. Blood. 2004;104(11):Abstract 73.
34. Wuilleme S, Robillard N, Lode L, Magrangeas F, Beris H, Harousseau JL, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005;19 (2):275-278.
35. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood. 1998;92(5):1743-1748.
36. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, et al. Multicolor spectral karyotyping of human chromosomes. Science. 1996;273(5274): 494-497.
37. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood. 1998;92(11):4269-4278.
38. Telenius H, Pelmear AH, Tunnacliffe A, Carter NP, Behmel A, Ferguson-Smith MA, et al. Cytogenetic analysis by chromosome painting using DOP-PCR amplified flowsorted chromosomes. Genes Chromosomes Cancer. 1992;4(3):257-263.
39. Shaffer LG TN, eds. ISCN 2005. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger. 2005.
40. Reme T, Hose D, De Vos J, Vassal A, Poulain PO, Pantesco V, et al. A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics. 2008;9: 16.
41. Assou S, Le Carrour T, Tondeur S, Strom S, Gabelle A, Marty S, et al. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells. 2007;25(4):961-973.
42. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
43. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.
44. Hose D, DeVos J, Muller N, Rossi JF, Heib C, Mahtouk K, et al. Clonal and subclonal cytogenetic aberrations: association with D-type cyclin expression and event-free survival (EFS) in multiple myeloma (MM). Blood. 2006;108(11):982a-982a.
45. Hose D, Reme T, Hielscher T, Moreaux J, Meissner T, Seckinger A, et al. Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica. 2011;96(1):87-95.
46. Hose D, Reme T, Hielscher T, Moreaux J, Meissner T, Seckinger A, et al. A gene expression based proliferation index as independent prognostic factor in multiple myeloma. Blood. 2008; 112(11):589.